News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
YM BioSciences Completes Pivotal Phase III Trial Recruitment
October 21, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA). David Allan, Chairman and CEO, will be presenting at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
MORE ON THIS TOPIC
Insights
Automation, Collaboration and the Future of Advanced Therapies
April 9, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Dermatology
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
April 8, 2026
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
April 8, 2026
·
1 min read
·
Heather McKenzie
Insights
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential
April 8, 2026
·
3 min read
·
Jennifer C. Smith-Parker
